GlassScriptPhysician profile
Chintamaneni P Choudari
NPI 1538148283
$2,164.78
in general payments reported to CMS, 2019-2025
21 companies · $80.74 in 2025
The $80.74 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $128 · 2021: $595 · 2022: $498 · 2023: $494 · 2024: $369 · 2025: $80.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $845.77 | 2020-2024 | Epclusa |
| Abbvie INC. | $289.58 | 2021-2022 | |
| Celgene Corporation | $235.18 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.14 | 2020-2023 | Trulance |
| Phathom Pharmaceuticals, INC. | $206.59 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $97.30 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $40.42 | 2024-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $29.58 | 2021 | |
| Aimmune Therapeutics, INC. | $28.13 | 2023 | |
| Madrigal Pharmaceuticals | $21.67 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $20.93 | 2023 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $19.15 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.60 | 2021 | |
| Genzyme Corporation | $18.34 | 2024 | |
| Amgen INC. | $16.67 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $16.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.52 | 2022 | |
| Olympus America INC. | $13.64 | 2024 | Endoclot Phs |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chintamaneni Choudari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.